医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Novogene Acquires an Illumina HiSeq X Ten Sequencing System

2014年02月13日 PM08:55
このエントリーをはてなブックマークに追加


 

SAN DIEGO

Illumina, Inc. (NASDAQ:ILMN) today announced that Novogene (www.novogene.cn), a leading genomics service provider based in Beijing, China, purchased one HiSeq X Ten. This strategic investment expands Novogene’s capacity with Illumina’s next-generation sequencing systems, which also includes HiSeqs and MiSeqs.

“The HiSeq X Ten will enhance our capability for cancer genomics and for mapping human disease genes, while enabling us to do population sequencing,” said Dr. Ruiqiang Li, CEO of Novogene.

“We are excited Novogene is investing in the HiSeq X Ten to further accelerate cancer and genetic disease research in China,” said Jay Flatley, CEO of Illumina. “Novogene’s portfolio provides the power to conduct the full range of next-generation sequencing applications from population scale sequencing, on the HiSeq X Ten, to exomes, targeted panels and RNA applications on HiSeq and MiSeq.”

The HiSeq X Ten is the world’s first platform to deliver full coverage human genomes for less than $1,000, including typical instrument depreciation, DNA extraction, library preparation, and estimated labor. Purpose-built for population-scale human whole genome sequencing, the HiSeq X Ten can sequence tens of thousands of samples annually with high-quality, high-coverage sequencing. It is sold as a set of 10 or more ultra-high throughput sequencing systems, each generating up to 1.8 terabases (Tb) of sequencing data in less than three days or up to 600 gigabases (Gb) per day, per system.

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.

CONTACT

Illumina, Inc.
Investors:
Rebecca Chambers,
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer
Temple, 858-882-6822
pr@illumina.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • PotNetwork Holdings, Inc.第三季度业绩创纪录,营收超过610万美元
  • ポットネットワーク・ホールディングスが610万ドルを超える収益で過去最高の第3四半期を終える
  • ポットネットワーク・ホールディングスがSEC報告会社となるためにフォーム10を提出
  • Sinovac Granted Interim Injunctive Relief Regarding Filings Bearing a Falsified Company Seal and Forged Board Member Signatures
  • 2018年江戸川NICHE賞は幹細胞発見の功績によりジェームズ・ティル教授に授与へ